Serbia Pharmaceuticals and Healthcare Report Q3 2013:Life Sciences Market Research Reports

Life Sciences Market Research Reports

Serbia Pharmaceuticals and Healthcare Report Q3 2013 Jul 17th 2013, 00:00, by rnrmahesh BMI View: While the market is small in absolute volume terms, relative per capita spending on medicines is expected to improve over the long term. As the country continues its economic convergence with developed Europe, drug consumption is also expected to rise. However, financial inefficiencies within the health insurance system mean that the National Health Insurance Institution (RZZO) is unable to always meet its obligations on time, leaving patients to pay for formerly reimbursed medicines or hospitals having to cover the difference. Headline Expenditure Projections ? Pharmaceuticals: RSD81.38bn (US$0.93bn) in 2012 to RSD91.16bn (US$1.10bn) in 2013; +12.0% in local currency … Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=107797. Complete report details with Table of Contents and more @ http://www.rnrmarketresearch.com/serbia-pharmaceuticals-and-healthcare-report-q3-2013-market-report.html.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions